- AstraZeneca's oncology head defended global dealmaking, citing high-quality R&D in China.
AstraZeneca's oncology head said the company should be able to source medicines globally, as the U.S. and China move to restrict biotech investment flows. Both countries exempted licensing deals, which AstraZeneca has used heavily in China, including a deal valued at up to $18.5 billion with CSPC Pharmaceutical Group.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.